Envoy Medical FY2026 EPS Forecast Raised by HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS forecast for Envoy Medical to a loss of $0.31 per share from $0.32, while maintaining a “Buy” rating and $2.00 price target.
• Analyst sentiment is mixed: coverage includes one Buy, one Hold and one Sell rating, resulting in an overall “Hold” consensus and an average $2.00 price target.
• Envoy Medical reported a quarterly loss of $0.07 per share, beating estimates by $0.01, on revenue of approximately $50,000. The stock opened at $0.75, with institutional investors owning 8.59% of shares.

Envoy Medical, Inc. (NASDAQ:COCH - Free Report) - Investment analysts at HC Wainwright raised their FY2026 earnings estimates for Envoy Medical in a research note issued to investors on Friday, August 21st. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.31) for the year, up from their prior estimate of ($0.32). HC Wainwright has a "Buy" rating and a $2.00 price target on the stock. The consensus estimate for Envoy Medical's current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Envoy Medical's Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.18) EPS.

Other equities analysts also recently issued research reports about the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Envoy Medical in a report on Tuesday, July 21st. Loop Capital set a $2.00 price target on shares of Envoy Medical in a report on Monday, July 27th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $2.00.

Envoy Medical Trading Down 0.5%

Shares of NASDAQ COCH opened at $0.75 on Tuesday. Envoy Medical has a one year low of $0.36 and a one year high of $1.89. The firm has a market capitalization of $57.60 million, a PE ratio of -0.98 and a beta of 1.90. The business has a 50-day moving average price of $0.70 and a two-hundred day moving average price of $0.69.

Envoy Medical (NASDAQ:COCH - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The business had revenue of $0.05 million during the quarter, compared to analysts' expectations of $0.05 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. DSG Capital Advisors LLC bought a new stake in Envoy Medical in the first quarter worth approximately $416,000. Focus Partners Wealth bought a new position in shares of Envoy Medical during the 1st quarter valued at $276,000. CIBC Bancorp USA Inc. bought a new position in shares of Envoy Medical during the 3rd quarter valued at $60,000. Finally, Geode Capital Management LLC lifted its stake in shares of Envoy Medical by 111.3% in the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company's stock valued at $65,000 after purchasing an additional 51,813 shares during the last quarter. Hedge funds and other institutional investors own 8.59% of the company's stock.

About Envoy Medical

Envoy Medical NASDAQ: COCH is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company's lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical's flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source